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Mammography screening has become a popular
public health intervention. However, the benefit of
systematic population screening programs is
controversial. This raises a number of ethical issues:
How should disadvantages of screening – in
particular overdiagnosis – be weighed against its
potential benefits?What do women need to know in
order to make an informed decision for or against
screening? Should scarce public resources be
invested in a program with unclear effectiveness?
The will discuss these issues, outlinepresentation
the recent policy debate in Switzerland, and suggest
somepoints for further consideration.
Mammography screening has become a popular
public health intervention. According to figures of
the International Agency for Research on Cancer
(IARC), the specialized cancer agency of the World
Health Organization, breast cancer is the most
frequently diagnosed cancer among women
worldwide. In 2012, 522.000 women worldwide
died frombreast cancer, and 1.7millionwomenwere
newly diagnosed that year.
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So breast cancer is both a serious challenge,
sometimes a tragedy for individual patients and their
families, and an important public health challenge.
There is no doubt that reducing the breast cancer
burden is an ethical imperative. It seems that one
way to go would be to focus on early diagnosis,
which would lead to more gentle yet effective
treatment, which would again save lives or at least
somequality of life.
Mammography has been promoted over the past
decades as a tool that would help screen large
populations of women. However, the benefits of
systematic population screening programs have
remained controversial.Where population screening
is used there seems to be no reduction of overall
mortality nor of cancer-specific mortality. Whereas
some studies do not find any reduction of breast-
cancer-specific mortality either, others claim a 20%
reduction of relative risk which is however likely to
be lower for women below the age of 45. That means
that if you screen 10.000 women annually at age 40
for 10 years, about 200 cancers will be detected and
about 30 womenwill die of breast cancer - instead of
35 thatwould have diedwithout screening.
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Even if we assume that the benefit of about 20%
relative risk reduction is real there are significant
risks and burdens that come with screening. One
issue concerns false negatives, when a cancer is
missed.Another issue is unclear test results that lead
to a second mammogram or other imaging tests like
ultrasound. The proportion of women called in for a
second test maybe as high as 60%, and up to 10% of
all women screened will be asked for a biopsy. The
additional tests can be expected to cause
considerable anxiety, withwomen and their relatives
worrying intensely about the test results.
The major issue from an ethical perspective,
however, is overdiagnosis. For each women who
may have been saved by screening, about 5 to 8
women will be diagnosed with a cancer that would
not have killed and likely never have bothered them.
As we cannot yet distinguish the aggressive cancers
well from the harmless ones, these women will be
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undergo the usual course of treatment, likely
including chemotherapy and radiotherapy as well as
surgery.
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This raises a number of ethical issues: How
should disadvantages of screening – in particular
overdiagnosis – be weighed against its potential
benefits? What do women need to know in order to
make an informed decision for or against screening?
Should scarce public resources be invested in a
program with unclear effectiveness? The Swiss
Medical Board (www.medical-board.ch), an
independent Health Technology Assessment
institution, has assessed mammography screening
and has reached the conclusion that – in the light of
the evidence currently available - the introduction of
new programs is not warranted, neither from a
clinical effectiveness nor from a cost-effectiveness
point of view.
Very recently, the American Cancer Society has
updated its guidelines on breast cancer screening,
reducing the recommended age span (starting at age
45 instead of 40) and frequency of testing (bi-
annually instead of annually from age 55 on). On its
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website, the society states: “Mammograms are not
perfect. They miss some cancers. And sometimes
more tests will be needed to find out if something
found on a mammogram is or is not cancer. There’s
also a small possibility of being diagnosed with a
cancer that never would have caused any problems
had it not been found during screening. It‘s
important that women getting mammograms know
what to expect and understand the benefits and
limitations of screening”.
5
Although it is very good that the relevant issues
are mentioned, there are no numbers that would help
patients understand the magnitude of positive and
negative effects. This information, however, is
crucial to weighing the pros and cons.We know that
women usually overestimate the benefits of
screening, so they need to be better informed.
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Rather than making sure women comply with and
adhere to screening programswe should enable them
to make a well-informed choice for or against
screening.
Many times, mammography screening is
discussed in a highly emotional way. However, we
should not simply stick to programs that cannot
show a convincing ratio of benefits vs. risks and
burden. The money invested there will be missing in
other places. Also, insisting on everyone having
access to mammography screening does not make
much sense in the absence as long as the benefits do
not clearly outweigh negative effects.
This is not to say that mammography should not
play an important role in individual diagnosis. Also,
it is very possible that we will be able to improve the
effectiveness of screening programs through better
imaging techniques that might allow us to better
differentiate harmful cancers from others. Risk
stratificationmay help us better target the population
that will benefit most. Further research will provide
the basis for building stronger programs that enable
us to reap the benefits of mammography screening
while minimizing the waste of precious public
resources and,most importantly, harm towomen.
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